Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Janux Therapeutics, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-22Dec-05-22Dec-31-21Dec-05-21Dec-31-20Dec-31-19
   10-K8-K10-K8-K10-KS-1/A
Revenues  8.653.43.626.20.03.0
            Revenue growth  136.8%103.7%  -100.0% 
Cost of goods sold  0.075.70.036.60.06.0
Gross profit  8.6-22.33.6-10.30.0-3.0
            Gross margin  100.0%-41.7%100.0%-39.4% -100.0%
Selling, general and administrative   [+]22.322.310.310.31.80.8
Research and development  53.4 26.2 3.0 
Other operating expenses   22.6 12.3  
EBITDA   [+]-66.3 -32.8 -4.8-3.8
            EBITDA margin  -769.3%-125.5%-902.3%-125.5% -125.5%
Depreciation and amortization  0.8 0.1 0.00.0
EBIT   [+]-67.1-67.1-32.9-32.9-4.8-3.8
            EBIT margin  -779.0%-125.5%-905.4%-125.5% -125.7%
Interest income  4.0 0.3   
Other income (expense), net   4.0 0.3-1.93.8
Pre-tax income  -63.1-63.1-32.7-32.7-6.80.0
Income taxes  0.00.00.00.00.00.0
            Tax rate  0.0%0.0%0.0%0.0%0.0% 
Net income  -63.1-63.1-32.7-32.7-6.80.0
            Net margin  -732.2%-118.0%-898.3%-124.5% 0.0%
   
Basic EPS   [+]($1.52)($1.52)($1.39)($1.39)($7.41)$0.00
Diluted EPS   [+]($1.52)($1.52)($1.39)($1.39)($7.41)$0.00
   
Shares outstanding (basic)   [+]41.541.523.523.50.9669.4
Shares outstanding (diluted)   [+]41.541.523.523.50.9669.4
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy